{
    "clinical_study": {
        "@rank": "74065", 
        "arm_group": [
            {
                "arm_group_label": "Cohort 1: AGN-223575 Formulation A", 
                "arm_group_type": "Experimental", 
                "description": "One drop of AGN-223575 Formulation A in the study eye and one drop of AGN-223575 vehicle in the other eye on day 1, followed by one drop of AGN-223575 Formulation A twice daily in the study eye and 1 drop of AGN-223575 vehicle in the other eye twice daily for 6 days."
            }, 
            {
                "arm_group_label": "Cohort 2: AGN-223575 Formulation A", 
                "arm_group_type": "Experimental", 
                "description": "One drop of AGN-223575 Formulation A in both eyes on day 1, followed by one drop of AGN-223575 Formulation A twice daily in both eyes for 13 days, and a single drop of AGN-223575 Formulation A in both eyes on day 15."
            }, 
            {
                "arm_group_label": "Cohort 3: AGN-223575 Formulation B", 
                "arm_group_type": "Experimental", 
                "description": "One drop of AGN-223575 Formulation B in both eyes on day 1, followed by one drop of AGN-223575 Formulation B twice daily in both eyes for 13 days, and a single drop of AGN-223575 Formulation B in both eyes on day 15."
            }, 
            {
                "arm_group_label": "Cohort 4: AGN-223575 Formulation C", 
                "arm_group_type": "Experimental", 
                "description": "One drop of AGN-223575 Formulation C in both eyes on day 1, followed by one drop of AGN-223575 Formulation C twice daily in both eyes for 13 days, and a single drop of AGN-223575 Formulation C in both eyes on day 15."
            }, 
            {
                "arm_group_label": "AGN-223575 Vehicle", 
                "arm_group_type": "Placebo Comparator", 
                "description": "One drop of AGN-223575 vehicle in both eyes on day 1, followed by one drop of AGN-223575 vehicle twice daily in both eyes for 13 days, and a single drop of AGN-223575 vehicle in both eyes on day 15."
            }
        ], 
        "brief_summary": {
            "textblock": "This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of AGN-223575\n      in healthy subjects."
        }, 
        "brief_title": "A Safety, Tolerability, and Pharmacokinetics (PK) Study of AGN-223575 in Healthy Subjects", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy Volunteers", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Weight at least 110 lbs\n\n        Exclusion Criteria:\n\n          -  Use of contact lenses within 14 days, or planned use during the study\n\n          -  Use of any ocular eye medications within 30 days, or anticipated use during the study\n\n          -  Anticipated use of any artificial tears product during the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "39", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 2, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02155543", 
            "org_study_id": "223575-001"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Cohort 1: AGN-223575 Formulation A", 
                    "Cohort 2: AGN-223575 Formulation A"
                ], 
                "description": "One drop of AGN-223575 Formulation A administered in the study eye(s) per protocol.", 
                "intervention_name": "AGN-223575 Formulation A", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Cohort 3: AGN-223575 Formulation B", 
                "description": "One drop of AGN-223575 Formulation B in both eyes on day 1, followed by one drop of AGN-223575 Formulation B twice daily in both eyes for 13 days, and a single drop of AGN-223575 Formulation B in both eyes on day 15.", 
                "intervention_name": "AGN-223575 Formulation B", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Cohort 4: AGN-223575 Formulation C", 
                "description": "One drop of AGN-223575 Formulation C in both eyes on day 1, followed by one drop of AGN-223575 Formulation C twice daily in both eyes for 13 days, and a single drop of AGN-223575 Formulation C in both eyes on day 15.", 
                "intervention_name": "AGN-223575 Formulation C", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Cohort 1: AGN-223575 Formulation A", 
                    "AGN-223575 Vehicle"
                ], 
                "description": "One drop of AGN-223575 vehicle administered in the study eye(s) per protocol.", 
                "intervention_name": "AGN-223575 Vehicle", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "June 2, 2014", 
        "link": {
            "description": "More Information", 
            "url": "http://www.allerganclinicaltrials.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Newport Beach", 
                    "country": "United States", 
                    "state": "California"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "5", 
        "overall_contact": {
            "email": "clinicaltrials@allergan.com", 
            "last_name": "Allergan Inc."
        }, 
        "overall_official": {
            "affiliation": "Allergan", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Plasma Levels of AGN-223575", 
            "safety_issue": "No", 
            "time_frame": "Day 15"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02155543"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Drop Tolerability Score", 
            "safety_issue": "No", 
            "time_frame": "Day 1, Day 2, Day 15"
        }, 
        "source": "Allergan", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Allergan", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}